DiaMedica Therapeutics Announces Final Closing of Private Placement
29 mars 2018 18h08 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...
DiaMedica Therapeutics Announces Closing of Private Placement
20 mars 2018 17h40 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...
DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
22 févr. 2018 07h00 HE
|
DiaMedica Therapeutics Inc.
DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of careREMEDY trial lead by prominent neurologist Dr. Bruce...
DiaMedica to Present at the 14th Annual Noble Investor Conference
29 janv. 2018 08h45 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital...
Satellite Healthcare to Present at American Society of Nephrology Annual Kidney Week Conference
31 oct. 2017 09h03 HE
|
Satellite Healthcare
SAN JOSE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Satellite Healthcare, a leading not-for-profit dialysis provider, today announced it will present three posters and host a NephTalk lounge for...
About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
13 juin 2017 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Chief Executive Officer Thomas B. Neff will participate...
Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
25 juil. 2016 21h00 HE
|
FibroGen, Inc.
TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) (“Astellas”) and FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), today announced the dosing of the first...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd
15 juin 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
09 juin 2016 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc....
U.S. FDA Approves Rockwell’s Triferic® Powder Packet for Treating Anemia in Hemodialysis Patients
26 avr. 2016 08h00 HE
|
Rockwell Medical, Inc.
WIXOM, Mich., April 26, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...